Register here to join our In Conversation Live with Kate Bingham
Kate Bingham is Managing Partner of SV Health Investors and the former Chair of the UK Vaccine Taskforce. As Chair of the Vaccine Taskforce in 2020, she led a team of world-class experts from across industry, science, academia, funding, regulators, logistics and government with the shared purpose of procuring and manufacturing COVID-19 vaccine/s as rapidly as possible. Kate will be joining Professor Sir Simon Wessely, RSM immediate Past-President, for a conversation about her career, the strategy and strive behind the UK’s historical COVID-19 vaccine effort, and how the pandemic has changed the biotech and pharmaceutical sector and public opinion.
Instead of charging for this webinar, we are asking people to support the Royal Society of Medicine in these unprecedented times. Now more than ever, we need your help to continue our work. Please consider making a donation for watching this webinar. Thank you for your generosity.
In May 2020, Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine on a six-month engagement, stepping down as Chair in December 2020. On December 8 2020 the UK started COVID-19 vaccinations - the first Western country to do so. The Vaccine Taskforce helped place the UK at the leading edge of the international effort to fight the pandemic through the development of clinically safe and effective vaccines.
Kate has worked in the biotech and life sciences sectors for 30 years and is Managing Partner at life sciences venture capital firm SV Health Investors and a board member of the Francis Crick Institute. Her investments have led to the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate is responsible for SV’s biotech investments and activities and serves, or has served, on the boards of companies in the UK, US, Ireland, Sweden and Germany. She played an active role in setting up the Dementia Discovery Fund (DDF) and supports the International Biotechnology Trust listed on the LSE.
She won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017 and has a first-class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).
Book your free place now
Join in the conversation online by using #RSMLive
Follow us on Twitter: @RoySocMed